Latest On GlaxoSmithKline plc (GLAXF):
| Date/Time | Type | Description | Signal | Details |
|---|---|---|---|---|
| 2024-02-22 05:13 EST | Dividend | A dividend of $0.16 has been announced on Nov 24, 2022. It will be paid Apr 11, 2024 with an ex-dividend date of Feb 22, 2024. | Neutral |  |
| 2023-11-16 04:56 EST | Dividend | A dividend of $0.14 has been announced on Nov 24, 2022. It will be paid Jan 11, 2024 with an ex-dividend date of Nov 16, 2023. | Neutral | |
| 2023-08-17 05:56 EST | Dividend | A dividend of $0.14 has been announced on Nov 24, 2022. It will be paid Oct 12, 2023 with an ex-dividend date of Aug 17, 2023. | Neutral | |
| 2023-05-18 05:56 EST | Dividend | A dividend of $0.14 has been announced on Nov 24, 2022. It will be paid Jul 13, 2023 with an ex-dividend date of May 18, 2023. | Neutral | |
| 2023-02-23 04:56 EST | Dividend | A dividend of $0.14 has been announced on Nov 24, 2021. It will be paid Apr 13, 2023 with an ex-dividend date of Feb 23, 2023. | Neutral | |
| 2023-01-07 07:46 EST | News | GSK: Near-Term Upside | N/A | |
| 2022-12-15 01:31 EST | News | GSK plc (GSK) Q3 2022 Earnings Call Transcript | N/A | |
| 2022-11-17 04:56 EST | Dividend | A dividend of $0.14 has been announced on Nov 24, 2021. It will be paid Jan 12, 2023 with an ex-dividend date of Nov 17, 2022. | Neutral | |
| 2022-11-01 02:11 EST | News | GSK plc (GSK) Citi's 17th Annual BioPharma Conference Earnings Call Transcript | N/A | |
| 2022-10-27 17:24 EST | News | GSK: Haleon Demerger Retrospective | N/A | |
| 2022-08-18 05:56 EST | Dividend | A dividend of $0.13 has been announced on Nov 24, 2021. It will be paid Oct 6, 2022 with an ex-dividend date of Aug 18, 2022. | Neutral | |
| 2022-07-28 02:00 EST | News | GSK plc (GLAXF) CEO Emma Walmsley on Q2 2022 Results - Earnings Call Transcript | N/A | |
| 2022-07-27 11:46 EST | News | GSK plc 2022 Q2 - Results - Earnings Call Presentation | N/A | |
| 2022-07-20 14:45 EST | News | GlaxoSmithKline plc (GSK) Management Presents at UBS Global Healthcare Conference (Transcript) | N/A | |
| 2022-07-20 14:41 EST | News | GSK plc (GSK) Goldman Sachs 43rd Annual Global Healthcare Conference (Transcript) | N/A | |
| 2022-07-20 14:41 EST | News | GSK Could Finally Be Turning A Corner | N/A | |
| 2022-07-20 14:41 EST | News | GSK plc (GSK) Management Presents at dbAcess Global Consumer Conference (Transcript) | N/A | |
| 2022-05-19 05:56 EST | Dividend | A dividend of $0.14 has been announced on Nov 24, 2021. It will be paid Jul 1, 2022 with an ex-dividend date of May 19, 2022. | Neutral | |
| 2022-04-29 15:39 EST | News | GlaxoSmithKline PLC (GSK) Investor Presentation - Slideshow | N/A | |
| 2022-03-31 22:08 EST | News | GlaxoSmithKline PLC (GSK) CEO Emma Walmsley on Q4 2021 Results - Earnings Call Transcript | N/A | |
| 2022-02-24 04:56 EST | Dividend | A dividend of $0.23 has been announced on Nov 27, 2020. It will be paid Apr 7, 2022 with an ex-dividend date of Feb 24, 2022. | Neutral | |
| 2022-02-11 12:15 EST | News | GlaxoSmithKline plc's (GSK) CEO Emma Walmsley Presents at JPMorgan 40th Annual Healthcare Conference (Transcript) | N/A | |
| 2022-02-10 18:44 EST | News | GlaxoSmithKline plc CEO Emma Walmsley at JP Morgan Healthcare Conference 2022 | N/A | |
| 2022-02-09 22:24 EST | News | 908 Devices announces GlaxoSmithKline purchases additional Rebel analyzer | N/A | |
| 2022-02-01 18:46 EST | News | GlaxoSmithKline: Healthcare GARP Following Separation | N/A | |
| 2022-01-23 19:52 EST | News | GlaxoSmithKline (GSK) Investor Presentation - Slideshow | N/A | |
| 2022-01-19 20:38 EST | News | GlaxoSmithKline (GSK) Presents At Investor Science Event at ASN Kidney Week 2021 | N/A | |
| 2021-11-18 04:56 EST | Dividend | A dividend of $0.19 has been announced on Nov 27, 2020. It will be paid Jan 13, 2022 with an ex-dividend date of Nov 18, 2021. | Neutral | |
| 2021-08-19 05:58 EST | Dividend | A dividend of $0.19 has been announced on Nov 27, 2020. It will be paid Oct 7, 2021 with an ex-dividend date of Aug 19, 2021. | Neutral | |
| 2021-08-18 20:40 EST | News | GlaxoSmithKline (GSK) Presents At CECP Biopharma Investor Forum - Slideshow | N/A | |
| 2021-08-18 00:08 EST | News | GlaxoSmithKline (GSK) Presents At BNP Paribas 23rd European CEO Conference - Slideshow | N/A | |
| 2021-08-03 03:02 EST | News | GlaxoSmithKline: Gem In Consumer Healthcare, Deflation Resistant, Keep Watch | N/A | |
| 2021-07-28 13:14 EST | News | GlaxoSmithKline plc (GSK) CEO Emma Walmsley Presents at CECP's Biopharma Investor Forum Conference (Transcript) | N/A | |
| 2021-05-20 05:58 EST | Dividend | A dividend of $0.19 has been announced on Nov 27, 2020. It will be paid Jul 8, 2021 with an ex-dividend date of May 20, 2021. | Neutral | |
| 2021-04-29 01:51 EST | News | GlaxoSmithKline plc (GSK) Presents at Barclays Global Healthcare Conference 2021 (Transcript) | N/A | |
| 2021-04-24 00:09 EST | News | GlaxoSmithKline plc (GSK) Presents at Cowen 41st Annual Health Care Conference (Transcript) | N/A | |
| 2021-03-29 21:01 EST | News | GlaxoSmithKline plc 2020 Q4 - Results - Earnings Call Presentation | N/A | |
| 2021-02-26 10:23 EST | News | GlaxoSmithKline (GSK) Presents At Morgan Stanley ESG Conference 2020 - Slideshow | N/A | |
| 2021-02-18 04:57 EST | Dividend | A dividend of $0.23 has been announced on Jan 8, 2020. It will be paid Apr 8, 2021 with an ex-dividend date of Feb 18, 2021. | Neutral | |
| 2021-02-05 09:07 EST | Financials | Company financials have been released. | Neutral | |
| 2021-02-04 09:03 EST | Earnings Estimate | An EPS average of $122.12 is estimated for the 2022 year. | Buy | |
| 2021-02-04 09:03 EST | Earnings Estimate | An EPS average of $22.40 is estimated for the quarter ending on June 30, 2021. | Sell | |
| 2021-01-19 20:15 EST | News | GlaxoSmithKline: Growth Only A Couple Of Years Away | N/A | |
| 2021-01-03 10:56 EST | News | GlaxoSmithKline Or AbbVie: Choices In High-Yield Pharma | N/A | |
| 2020-12-22 11:34 EST | News | GlaxoSmithKline PLC (GSK) CEO Emma Walmsley on Q3 2020 Results - Earnings Call Transcript | N/A | |
| 2020-12-21 18:04 EST | News | GlaxoSmithKline plc 2020 Q3 - Results - Earnings Call Presentation | N/A | |
| 2020-11-26 22:15 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-12 04:58 EST | Dividend | A dividend of $0.19 has been announced on Jan 8, 2020. It will be paid Jan 14, 2021 with an ex-dividend date of Nov 12, 2020. | Neutral | |
| 2020-11-08 01:25 EST | Financials | Company financials have been released. | Neutral | |
| 2020-11-07 17:42 EST | Financials | Company financials have been released. | Neutral | |
About GlaxoSmithKline plc (GLAXF):
GlaxoSmithKline plc engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as respiratory, HIV, immuno-inflammation, oncology, anti-viral, central nervous system, cardiovascular and urogenital, metabolic, anti-bacterial, and dermatology. It also provides consumer healthcare products in wellness, oral health, nutrition, and skin health categories. The company offers its consumer healthcare products in the form of nasal sprays, tablets, syrups, lozenges, gum and trans-dermal patches, caplets, infant syrup drops, liquid filled suspension, wipes, gels, effervescents, toothpastes, toothbrushes, mouthwashes, denture adhesives and cleansers, topical creams and non-medicated patches, lip balm, gummies, and soft chews. It has collaboration agreements with 23andMe; Merck KGaA; Lyell Immunopharma; Novartis; CEPI; Innovax and Xiamen University; VBI; Viome; Sanofi SA; and CureVac. The company also has an agreement with Vir Biotechnology, Inc for research and development of new therapies for influenza and other respiratory viruses. GlaxoSmithKline plc was founded in 1715 and is headquartered in Brentford, the United Kingdom.
General
- Name GlaxoSmithKline plc
- Symbol GLAXF
- Type Common Stock
- Exchange PINK
- Currency USD
- Country USA
- SectorHealthcare
- IndustryDrug Manufacturers-General
- Full Time Employees 94,066
- Fiscal Year EndDecember
- Web URLhttp://www.gsk.com
View More
Valuation
- Trailing PE 35.54
- Forward PE 12.99
- Price/Sales (Trailing 12 Mt.) 1.9
- Price/Book (Most Recent Quarter) 4.43
- Enterprise Value Revenue 3.5
- Enterprise Value EBITDA 14.05
View More
Financials
- Most Recent Quarter 2020-12-31
- Current Year EPS Estimate $103.84
- Next Year EPS Estimate $114.25
- Next Quarter EPS Estimate $28.95
- Profit Margin 17%
- Return on Assets 7%
- Return on Equity 33%
- Earnings Per Share $0.50
- Revenue Per Share $0
- Gross Profit 23.21 billion
- Quarterly Earnings Growth -1.8%
View More
ESG Rating
Highlights
- Market Capitalization 88.84 billion
- PE Ratio 13.57
- PEG Ratio 8.77
- Book Value Per Share $1.20
View More
Share Statistics
- Shares Outstanding 5.03 billion
- Shares Float 4.89 billion
- % Held by Insiders 90%
- % Held by Institutions 50.82%
View More
Technicals
- Beta 0.35
- 52 Week High $20.83
- 52 Week Low $14.17
- 50 Day Moving Average 17.5
- 200 Day Moving Average 18.28
View More
Dividends
- Forward Annual Dividend Rate $1.07
- Forward Annual Dividend Yield 5.96%
- Payout Ratio 4%
- Dividend Date 2016-04-14
- ExDividend Date 2021-02-18
- Dividend Per Share $1.06
- Dividend Yield 0%
View More
GlaxoSmithKline plc (GLAXF) Dividend Calendar:
GLAXF's last dividend payment was made to shareholders on April 14, 2016.
GlaxoSmithKline plc pays out 4% of its earnings out as a dividend.
| Ex-Dividend Date | Payment Date | Record Date | Declared Date | Amount |
|---|
GlaxoSmithKline plc (GLAXF) Earnings History:
Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.
| Quarter Date | Report Date | Actual Revenue | Reported EPS | EPS Estimate | Deviation from Estimate |
|---|---|---|---|---|---|
| 2020-12-31 | 2020-12-31 | $N/A | $23.30 | $23.15 | 0.65% |
| 2020-09-30 | 2020-12-31 | $8.65 billion | $0.18 | $30.43 | -99.39% |
| 2020-06-30 | 2020-09-30 | $N/A | $0.32 | $20.00 | -98.41% |
| 2020-03-31 | 2020-06-30 | $9.09 billion | $0.56 | $32.15 | -98.27% |
| 2019-12-31 | 2020-03-31 | $11.81 billion | $0.39 | $25.63 | -98.49% |
| 2019-09-30 | 2019-12-31 | $11.54 billion | $0.34 | $33.61 | -98.98% |
| 2019-06-30 | 2019-09-30 | $9.92 billion | $0.38 | $25.46 | -98.5% |
| 2019-03-31 | 2019-06-30 | $10.04 billion | $0.25 | $25.24 | -99.03% |
| 2018-12-31 | 2019-03-31 | $10.46 billion | $0.22 | $27.52 | -99.21% |
| 2018-09-30 | 2018-12-31 | $10.55 billion | $0.31 | $32.70 | -99.05% |
| 2018-06-30 | 2018-09-30 | $9.61 billion | $0.37 | $25.83 | -98.56% |
| 2018-03-31 | 2018-06-30 | $10.14 billion | $0.12 | $24.28 | -99.52% |
| 2017-12-31 | 2018-03-31 | $10.31 billion | $0.16 | $25.87 | -99.4% |
| 2017-09-30 | 2017-12-31 | $10.41 billion | -$0.15 | $32.15 | -100.47% |
| 2017-06-30 | 2017-09-30 | $7.32 billion | $0.33 | $26.54 | -98.76% |
| 2017-03-31 | 2017-06-30 | $7.38 billion | -$0.05 | $24.53 | -100.2% |
| 2016-12-31 | 2017-03-31 | $7.59 billion | $0.27 | $25.04 | -98.93% |
| 2016-09-30 | 2016-12-31 | $0.06 | $29.84 | -99.78% | |
| 2016-06-30 | 2016-09-30 | $0.21 | $21.03 | -98.98% | |
| 2016-03-31 | 2016-06-30 | -$0.12 | $17.82 | -100.67% | |
| 2015-12-31 | 2016-03-31 | $0.08 | $18.08 | -99.54% | |
| 2015-09-30 | 2015-12-31 | -$0.11 | $19.21 | -100.56% | |
| 2015-06-30 | 2015-09-30 | $0.17 | $16.27 | -98.98% | |
| 2015-03-31 | 2015-06-30 | $0.05 | $17.58 | -99.72% | |
| 2014-12-31 | 2015-03-31 | $2.47 | $26.63 | -90.72% | |
| 2014-09-30 | 2014-12-31 | $0.33 | $24.10 | -98.62% | |
| 2014-06-30 | 2014-09-30 | $0.13 | $21.38 | -99.38% | |
| 2014-03-31 | 2014-06-30 | $0.23 | $20.73 | -98.89% | |
| 2013-12-31 | 2014-03-31 | $0.23 | $30.53 | -99.25% | |
| 2013-09-30 | 2013-12-31 | $0.84 | |||
| 2013-06-30 | 2013-09-30 | $0.32 | |||
| 2013-03-31 | 2013-06-30 | $0.32 | |||
| 2012-12-31 | 2013-03-31 | $0.30 | |||
| 2012-09-30 | 2012-12-31 | $0.28 | |||
| 2012-06-30 | 2012-09-30 | $0.36 | |||
| 2012-03-31 | 2012-06-30 | $0.39 | |||
| 2011-12-31 | 2012-03-31 | $0.42 | |||
| 2011-09-30 | 2011-12-31 | $0.39 | |||
| 2011-06-30 | 2011-09-30 | $0.43 | |||
| 2011-03-31 | 2011-06-30 | $0.35 | |||
| 2010-12-31 | 2011-03-31 | $0.48 | |||
| 2010-09-30 | 2010-12-31 | -$0.21 | |||
| 2010-06-30 | 2010-06-30 | -$0.09 | |||
| 2010-03-31 | 2010-03-31 | $0.41 | |||
| 2009-12-31 | 2009-12-31 | $0.52 | |||
| 2009-09-30 | 2009-09-30 | $0.43 | |||
| 2009-06-30 | 2009-06-30 | $0.44 | |||
| 2009-03-31 | 2009-03-31 | $0.32 | |||
| 2008-12-31 | 2008-12-31 | $0.30 | |||
| 2008-09-30 | 2008-09-30 | $0.38 | |||
| 2008-06-30 | 2008-06-30 | $0.48 | |||
| 2008-03-31 | 2008-03-31 | $0.48 | |||
| 2007-12-31 | 2007-12-31 | $0.40 | |||
| 2007-09-30 | 2007-09-30 | $0.48 | |||
| 2007-06-30 | 2007-06-30 | $0.47 | |||
| 2007-03-31 | 2007-03-31 | $0.52 | |||
| 2006-12-31 | 2006-12-31 | $0.40 | |||
| 2006-09-30 | 2006-09-30 | $0.46 | |||
| 2006-06-30 | 2006-06-30 | $0.42 | |||
| 2006-03-31 | 2006-03-31 | $0.46 | |||
| 2005-12-31 | 2005-12-31 | $0.34 | |||
| 2005-09-30 | 2005-09-30 | $0.38 | |||
| 2005-06-30 | 2005-06-30 | $0.38 | |||
| 2005-03-31 | 2005-03-31 | $0.40 | |||
| 2004-06-30 | 2004-06-30 | $0.36 |
GlaxoSmithKline plc (GLAXF) Company Financial Statements:
Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.
Income Statement:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Research Development | N/A | 1.14 billion | N/A | 1.19 billion | 1.57 billion |
| Income Before Tax | N/A | 1.67 billion | N/A | 1.84 billion | 2.27 billion |
| Selling General Administrative | N/A | 2.67 billion | N/A | 2.92 billion | 4.35 billion |
| Gross Profit | N/A | 5.76 billion | N/A | 5.89 billion | 7.81 billion |
| Ebit | N/A | 2.51 billion | N/A | 2.26 billion | 2.01 billion |
| Operating Income | N/A | 1.86 billion | N/A | 2.01 billion | 2.01 billion |
| Income Tax Expense | -18 million | 241 million | 201 million | 156 million | 257.43 million |
| Total Revenue | N/A | 8.65 billion | N/A | 9.09 billion | 11.81 billion |
| Cost of Revenue | N/A | 2.89 billion | N/A | 3.2 billion | 4 billion |
| Total Other Income Expense Net | N/A | N/A | N/A | N/A | 264.07 million |
| Net Income From Continuing Operations | N/A | 1.43 billion | N/A | 1.68 billion | 2.01 billion |
| Net Income Applicable to Common Shares | 677 million | 1.24 billion | 2.26 billion | 1.57 billion | 1.72 billion |
Cash Flow:
| Date | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 | Sep 30 2019 |
|---|---|---|---|---|---|
| Investments | N/A | N/A | -58 million | -7.96 million | -218.78 million |
| Change to Liabilities | N/A | N/A | N/A | N/A | N/A |
| Total Cash Flow from Investing Activities | -560 million | 2.83 billion | -58 million | -490.98 million | -575.22 million |
| Net Borrowings | -2.88 billion | -606 million | -169 million | -1.65 billion | -919.37 million |
| Total Cash Flow from Financial Activities | N/A | N/A | N/A | -3.66 billion | -2.27 billion |
| Change to Operating Activities | -672 million | 1.57 billion | -796 million | 2.23 billion | 325.71 million |
| Change in Cash | N/A | N/A | -145 million | 294.59 million | 249.51 million |
| Total Cash from Operating Activities | 861 million | 2.76 billion | 965 million | 4.58 billion | 3.09 billion |
| Depreciation | N/A | N/A | 194 million | 585.19 million | 630.53 million |
| Other Cash Flow from Investing Activities | 7 million | 8 million | 18 million | 30.52 million | 36.87 million |
| Change to Inventory | N/A | N/A | N/A | N/A | N/A |
| Change to Account Receivables | N/A | N/A | N/A | N/A | N/A |
| Other Cash Flow from Financing Activities | -450 million | -2.03 billion | 35 million | -773.62 million | -208.95 million |
| Change to Net Income | -352 million | 91 million | 2 million | 39.81 million | 227.38 million |
| Capital Expenditures | N/A | N/A | 344 million | 636.94 million | 349.07 million |
Balance Sheet:
| Date | Dec 31 2020 | Sep 30 2020 | Jun 30 2020 | Mar 31 2020 | Dec 31 2019 |
|---|---|---|---|---|---|
| Total Liabailities | N/A | 60.3 billion | 64.5 billion | 64.29 billion | 81.39 billion |
| Total Stockholder Equity | N/A | 14.29 billion | 13.59 billion | 13.09 billion | 15.9 billion |
| Other Current Liabilities | 2.58 billion | 776 million | 804 million | 796 million | 4.25 billion |
| Total Assets | N/A | 80.93 billion | 84.64 billion | 84.38 billion | 105.75 billion |
| Common Stock | 1.35 billion | 1.35 billion | 1.35 billion | 1.35 billion | 1.79 billion |
| Other Current Assets | 258 million | 654 million | N/A | N/A | 1.72 billion |
| Retained Earnings | 6.76 billion | 7.06 billion | 6.62 billion | 6.35 billion | 6.78 billion |
| Other Liabilities | 14.05 billion | 14.79 billion | 14.85 billion | 14.21 billion | 18.17 billion |
| Other Assets | 5.33 billion | 5.32 billion | 5.41 billion | 6.37 billion | 6.93 billion |
| Cash | N/A | 4.28 billion | 8.17 billion | 4.77 billion | 6.25 billion |
| Total Current Liabilities | 22.15 billion | 22.18 billion | 23.92 billion | 25.34 billion | 31.91 billion |
| Other Stockholder Equity | 3.21 billion | 2.61 billion | 2.35 billion | 2.12 billion | 3.13 billion |
| Property, Plant & Equipment | 11.01 billion | 11.21 billion | 11.43 billion | 11.4 billion | 15.01 billion |
| Total Current Assets | 20.25 billion | 19.88 billion | 22.98 billion | 22.02 billion | 25.86 billion |
| Long Term Investments | N/A | N/A | N/A | N/A | 2.85 billion |
| Net Tangible Assets | -25.83 billion | -27.27 billion | -28.67 billion | -29.3 billion | -39.19 billion |
| Short Term Investments | N/A | 83 million | 87 million | 86 million | 104.83 million |
| Long Term Debt | N/A | N/A | N/A | N/A | 31.3 billion |
| Inventory | 6 billion | 6.44 billion | 6.4 billion | 5.95 billion | 7.89 billion |
| Accounts Payable | 15.84 billion | 15.14 billion | 15.45 billion | 15.31 billion | 18.48 billion |
GlaxoSmithKline plc (GLAXF) Chart:
GlaxoSmithKline plc (GLAXF) News:
Below you will find a list of latest news for GlaxoSmithKline plc (GLAXF) from major news sources. You can filter the results to only show news from a specific source.
No recent news available
GlaxoSmithKline plc (GLAXF) Options:
A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.
| Expiration Date | Strike | Last Price | Type | Volume | Open Interest | Implied Volatility | In The Money | Change | Change Percent |
|---|
GlaxoSmithKline plc (GLAXF) SEC Filings:
An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.
| Date | Form Type | Form Name | Link |
|---|